The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular profiling in gynecologic cancer and matched targeted therapy: A step toward improving personalized medicine.
Ana C. Garrido-Castro
No relevant relationships to disclose
Guillem Argilés
No relevant relationships to disclose
Debora Moreno
No relevant relationships to disclose
Victor Rodriguez-Freixinos
No relevant relationships to disclose
Marta Vilaro
No relevant relationships to disclose
Teresa Macarulla
No relevant relationships to disclose
Cristina Cruz Zambrano
No relevant relationships to disclose
Analia Azaro
No relevant relationships to disclose
Barbara Adamo
No relevant relationships to disclose
Maria Alsina
No relevant relationships to disclose
Jose Jimenez
No relevant relationships to disclose
Paolo Nuciforo
No relevant relationships to disclose
Ana Vivancos
No relevant relationships to disclose
Alba Meire
No relevant relationships to disclose
Jose Maria Del Campo
No relevant relationships to disclose
Jordi Rodon
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche; Sanofi ; Taiho Pharmaceutical
Ana Oaknin
No relevant relationships to disclose